138 related articles for article (PubMed ID: 23107871)
1. Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
Graham RA; Chang I; Jin JY; Wang B; Dufek MB; Ayache JA; Ezzet F; Zerivitz K; Low JA; Dresser MJ
J Cardiovasc Pharmacol; 2013 Jan; 61(1):83-9. PubMed ID: 23107871
[TBL] [Abstract][Full Text] [Related]
2. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
[TBL] [Abstract][Full Text] [Related]
4. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
7. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
[TBL] [Abstract][Full Text] [Related]
8. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
9. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
[TBL] [Abstract][Full Text] [Related]
10. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
[TBL] [Abstract][Full Text] [Related]
11. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
Miles DR; Lacy SA; Wada DR; Milwee S; Yaron Y; Nguyen LT
Cancer Chemother Pharmacol; 2017 Aug; 80(2):295-306. PubMed ID: 28634649
[TBL] [Abstract][Full Text] [Related]
13. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R; Dumortier T; Balez S
Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
[TBL] [Abstract][Full Text] [Related]
15. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
[TBL] [Abstract][Full Text] [Related]
16. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study.
Komatsu R; Honda M; Holzgrefe HH; Kubo J; Yamada Y; Isobe T; Kimura K; Itoh T; Tamaoki N; Tabo M
J Pharmacol Toxicol Methods; 2010; 61(3):271-6. PubMed ID: 20097298
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous zanamivir on cardiac repolarization.
Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
[TBL] [Abstract][Full Text] [Related]
19. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Spyker DA; Voloshko P; Heyman ER; Cassella JV
J Clin Pharmacol; 2014 Jun; 54(6):665-74. PubMed ID: 24375070
[TBL] [Abstract][Full Text] [Related]
20. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
Lee RD; Nudurupati S; Marcinak J; Viswanathan P
Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
